Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T12:45:46.924Z.
Calculation as of: 2026-10-06T12:45:46.924Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$1.52B
EV/EBITDA Ratio
73.17x
TTM Avg
329.18x
3Y Avg
230.60x
5Y Avg
237.22x
Market Cap
$1.46B
EV/EBITDA Ratio
11.73x
TTM Avg
34.83x
3Y Avg
34.83x
5Y Avg
32.76x
Market Cap
$1.45B
EV/EBITDA Ratio
8.97x
TTM Avg
18.38x
3Y Avg
16.03x
5Y Avg
16.85x
Market Cap
$1.43B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.65B
EV/EBITDA Ratio
57.39x
TTM Avg
223.11x
3Y Avg
223.11x
5Y Avg
223.11x
Market Cap
$1.65B
EV/EBITDA Ratio
6.87x
TTM Avg
10.54x
3Y Avg
14.62x
5Y Avg
19.17x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | $1.51B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.52B | N/A | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 73.17x | 329.18x | 230.60x | 237.22x |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | 11.73x | 34.83x | 34.83x | 32.76x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 8.97x | 18.38x | 16.03x | 16.85x |
| Certara, Inc. (CERT)vs › | $1.57B | 28.35x | 16.63x | 66.61x | 73.09x |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | 57.39x | 223.11x | 223.11x | 223.11x |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.65B | 6.87x | 10.54x | 14.62x | 19.17x |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.34B | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
